Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Increased miR-142-3p Expression Might Explain Reduced Regulatory T Cell Function in Granulomatosis With Polyangiitis.

Dekkema GJ, Bijma T, Jellema PG, Van Den Berg A, Kroesen BJ, Stegeman CA, Heeringa P, Abdulahad WH, Sanders JS.

Front Immunol. 2019 Sep 12;10:2170. doi: 10.3389/fimmu.2019.02170. eCollection 2019.

2.

Azathioprine Hypersensitivity Syndrome in a Cohort of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Patients.

Hessels AC, Sanders JSF, van de Ven AAJM, Kroesen BJ, Lambeck AJA, Rutgers A, Stegeman CA.

J Allergy Clin Immunol Pract. 2019 Mar;7(3):1004-1009. doi: 10.1016/j.jaip.2018.10.018. Epub 2018 Oct 24.

PMID:
30368003
3.

Involvement of MicroRNAs in the Aging-Related Decline of CD28 Expression by Human T Cells.

Teteloshvili N, Dekkema G, Boots AM, Heeringa P, Jellema P, de Jong D, Terpstra M, Brouwer E, Pawelec G, Kok K, van den Berg A, Kluiver J, Kroesen BJ.

Front Immunol. 2018 Jun 18;9:1400. doi: 10.3389/fimmu.2018.01400. eCollection 2018.

4.

Impact of Aging on the Frequency, Phenotype, and Function of CD161-Expressing T Cells.

van der Geest KSM, Kroesen BJ, Horst G, Abdulahad WH, Brouwer E, Boots AMH.

Front Immunol. 2018 Apr 19;9:752. doi: 10.3389/fimmu.2018.00752. eCollection 2018.

5.

Corrigendum to "Hodgkin Lymphoma Cell Lines Are Characterized by a Specific miRNA Expression Profile." Neoplasia 2009, Feb;11(2):167-176.

Gibcus JH, Tan LP, Harms G, Schakel RN, de Jong D, Blokzijl T, Möller P, Poppema S, Kroesen BJ, van den Berg A.

Neoplasia. 2018 Jan 28;20(2):226. doi: 10.1016/j.neo.2017.11.008. eCollection 2018 Feb.

6.

Argonaute 2 immunoprecipitation revealed large tumor suppressor kinase 1 as a novel proapoptotic target of miR-21 in T cells.

Teteloshvili N, Smigielska-Czepiel K, Yuan Y, Seitz A, de Jong D, Rutgers B, Jellema P, van der Lei RJ, Slezak-Prochazka I, Brouwer E, Boots AM, Kroesen BJ, van den Berg A, Kluiver J.

FEBS J. 2017 Feb;284(4):555-567. doi: 10.1111/febs.14011. Epub 2017 Feb 6.

7.

Analysis of serum immune markers in seropositive and seronegative rheumatoid arthritis and in high-risk seropositive arthralgia patients.

Chalan P, Bijzet J, van den Berg A, Kluiver J, Kroesen BJ, Boots AM, Brouwer E.

Sci Rep. 2016 May 18;6:26021. doi: 10.1038/srep26021.

8.

Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition.

van den Brom RR, Abdulahad WH, Rutgers A, Kroesen BJ, Roozendaal C, de Groot DJ, Schröder CP, Hospers GA, Brouwer E.

Rheumatology (Oxford). 2016 Jun;55(6):1143-5. doi: 10.1093/rheumatology/kew063. Epub 2016 Apr 11. No abstract available.

PMID:
27069016
9.

Altered Natural Killer Cell Subsets in Seropositive Arthralgia and Early Rheumatoid Arthritis Are Associated with Autoantibody Status.

Chalan P, Bijzet J, Kroesen BJ, Boots AM, Brouwer E.

J Rheumatol. 2016 Jun;43(6):1008-16. doi: 10.3899/jrheum.150644. Epub 2016 Apr 1.

PMID:
27036380
10.

Aging-dependent decline of IL-10 producing B cells coincides with production of antinuclear antibodies but not rheumatoid factors.

van der Geest KS, Lorencetti PG, Abdulahad WH, Horst G, Huitema M, Roozendaal C, Kroesen BJ, Brouwer E, Boots AM.

Exp Gerontol. 2016 Mar;75:24-9. doi: 10.1016/j.exger.2015.12.009. Epub 2015 Dec 23.

PMID:
26721376
11.

Inhibition of the miR-155 target NIAM phenocopies the growth promoting effect of miR-155 in B-cell lymphoma.

Slezak-Prochazka I, Kluiver J, de Jong D, Smigielska-Czepiel K, Kortman G, Winkle M, Rutgers B, Koerts J, Visser L, Diepstra A, Kroesen BJ, van den Berg A.

Oncotarget. 2016 Jan 19;7(3):2391-400. doi: 10.18632/oncotarget.6165.

12.

Age-Associated Differences in MiRNA Signatures Are Restricted to CD45RO Negative T Cells and Are Associated with Changes in the Cellular Composition, Activation and Cellular Ageing.

Teteloshvili N, Kluiver J, van der Geest KS, van der Lei RJ, Jellema P, Pawelec G, Brouwer E, Kroesen BJ, Boots AM, van den Berg A.

PLoS One. 2015 Sep 11;10(9):e0137556. doi: 10.1371/journal.pone.0137556. eCollection 2015.

13.

T-cell Activation Induces Dynamic Changes in miRNA Expression Patterns in CD4 and CD8 T-cell Subsets.

Teteloshvili N, Smigielska-Czepiel K, Kroesen BJ, Brouwer E, Kluiver J, Boots AM, van den Berg A.

Microrna. 2015;4(2):117-22.

PMID:
26290349
14.

Rheumatoid Arthritis, Immunosenescence and the Hallmarks of Aging.

Chalan P, van den Berg A, Kroesen BJ, Brouwer L, Boots A.

Curr Aging Sci. 2015;8(2):131-46. Review.

15.

Expression of Lectin-Like Transcript 1, the Ligand for CD161, in Rheumatoid Arthritis.

Chalan P, Bijzet J, Huitema MG, Kroesen BJ, Brouwer E, Boots AM.

PLoS One. 2015 Jul 6;10(7):e0132436. doi: 10.1371/journal.pone.0132436. eCollection 2015.

16.

Low-affinity TCR engagement drives IL-2-dependent post-thymic maintenance of naive CD4+ T cells in aged humans.

van der Geest KS, Abdulahad WH, Teteloshvili N, Tete SM, Peters JH, Horst G, Lorencetti PG, Bos NA, Lambeck A, Roozendaal C, Kroesen BJ, Koenen HJ, Joosten I, Brouwer E, Boots AM.

Aging Cell. 2015 Oct;14(5):744-53. doi: 10.1111/acel.12353. Epub 2015 May 25.

17.

Quantifying Distribution of Flow Cytometric TCR-Vβ Usage with Economic Statistics.

van der Geest KS, Abdulahad WH, Horst G, Lorencetti PG, Bijzet J, Arends S, van der Heiden M, Buisman AM, Kroesen BJ, Brouwer E, Boots AM.

PLoS One. 2015 Apr 29;10(4):e0125373. doi: 10.1371/journal.pone.0125373. eCollection 2015.

18.

Aging disturbs the balance between effector and regulatory CD4+ T cells.

van der Geest KS, Abdulahad WH, Tete SM, Lorencetti PG, Horst G, Bos NA, Kroesen BJ, Brouwer E, Boots AM.

Exp Gerontol. 2014 Dec;60:190-6. doi: 10.1016/j.exger.2014.11.005. Epub 2014 Nov 7.

PMID:
25449852
19.

SF Treg cells transcribing high levels of Bcl-2 and microRNA-21 demonstrate limited apoptosis in RA.

van der Geest KS, Smigielska-Czepiel K, Park JA, Abdulahad WH, Kim HW, Kroesen BJ, van den Berg A, Boots AM, Lee EB, Brouwer E.

Rheumatology (Oxford). 2015 May;54(5):950-8. doi: 10.1093/rheumatology/keu407. Epub 2014 Oct 21.

PMID:
25339644
20.

Immuno-miRs: critical regulators of T-cell development, function and ageing.

Kroesen BJ, Teteloshvili N, Smigielska-Czepiel K, Brouwer E, Boots AM, van den Berg A, Kluiver J.

Immunology. 2015 Jan;144(1):1-10. doi: 10.1111/imm.12367. Review.

21.

Comprehensive analysis of miRNA expression in T-cell subsets of rheumatoid arthritis patients reveals defined signatures of naive and memory Tregs.

Smigielska-Czepiel K, van den Berg A, Jellema P, van der Lei RJ, Bijzet J, Kluiver J, Boots AM, Brouwer E, Kroesen BJ.

Genes Immun. 2014 Mar;15(2):115-25. doi: 10.1038/gene.2013.69. Epub 2014 Jan 9.

22.

Circulating CD4+CD161+ T lymphocytes are increased in seropositive arthralgia patients but decreased in patients with newly diagnosed rheumatoid arthritis.

Chalan P, Kroesen BJ, van der Geest KS, Huitema MG, Abdulahad WH, Bijzet J, Brouwer E, Boots AM.

PLoS One. 2013 Nov 1;8(11):e79370. doi: 10.1371/journal.pone.0079370. eCollection 2013.

23.

Dual role of miR-21 in CD4+ T-cells: activation-induced miR-21 supports survival of memory T-cells and regulates CCR7 expression in naive T-cells.

Smigielska-Czepiel K, van den Berg A, Jellema P, Slezak-Prochazka I, Maat H, van den Bos H, van der Lei RJ, Kluiver J, Brouwer E, Boots AM, Kroesen BJ.

PLoS One. 2013 Oct 1;8(10):e76217. doi: 10.1371/journal.pone.0076217. eCollection 2013.

24.

Cellular localization and processing of primary transcripts of exonic microRNAs.

Slezak-Prochazka I, Kluiver J, de Jong D, Kortman G, Halsema N, Poppema S, Kroesen BJ, van den Berg A.

PLoS One. 2013 Sep 20;8(9):e76647. doi: 10.1371/journal.pone.0076647. eCollection 2013.

25.

Generation of miRNA sponge constructs.

Kluiver J, Slezak-Prochazka I, Smigielska-Czepiel K, Halsema N, Kroesen BJ, van den Berg A.

Methods. 2012 Oct;58(2):113-7. doi: 10.1016/j.ymeth.2012.07.019. Epub 2012 Jul 23.

PMID:
22836127
26.

Rapid generation of microRNA sponges for microRNA inhibition.

Kluiver J, Gibcus JH, Hettinga C, Adema A, Richter MK, Halsema N, Slezak-Prochazka I, Ding Y, Kroesen BJ, van den Berg A.

PLoS One. 2012;7(1):e29275. doi: 10.1371/journal.pone.0029275. Epub 2012 Jan 6.

27.

MiR-17/106b seed family regulates p21 in Hodgkin's lymphoma.

Gibcus JH, Kroesen BJ, Koster R, Halsema N, de Jong D, de Jong S, Poppema S, Kluiver J, Diepstra A, van den Berg A.

J Pathol. 2011 Dec;225(4):609-17. doi: 10.1002/path.2958. Epub 2011 Sep 26.

PMID:
21953646
28.

Human primary adipocytes exhibit immune cell function: adipocytes prime inflammation independent of macrophages.

Meijer K, de Vries M, Al-Lahham S, Bruinenberg M, Weening D, Dijkstra M, Kloosterhuis N, van der Leij RJ, van der Want H, Kroesen BJ, Vonk R, Rezaee F.

PLoS One. 2011 Mar 23;6(3):e17154. doi: 10.1371/journal.pone.0017154.

29.

MicroRNAs, macrocontrol: regulation of miRNA processing.

Slezak-Prochazka I, Durmus S, Kroesen BJ, van den Berg A.

RNA. 2010 Jun;16(6):1087-95. doi: 10.1261/rna.1804410. Epub 2010 Apr 27.

30.

A high throughput experimental approach to identify miRNA targets in human cells.

Tan LP, Seinen E, Duns G, de Jong D, Sibon OC, Poppema S, Kroesen BJ, Kok K, van den Berg A.

Nucleic Acids Res. 2009 Nov;37(20):e137. doi: 10.1093/nar/gkp715. Epub 2009 Sep 4.

31.

Endonucleases induced TRAIL-insensitive apoptosis in ovarian carcinoma cells.

Geel TM, Meiss G, van der Gun BT, Kroesen BJ, de Leij LF, Zaremba M, Silanskas A, Kokkinidis M, Pingoud A, Ruiters MH, McLaughlin PM, Rots MG.

Exp Cell Res. 2009 Sep 10;315(15):2487-95. doi: 10.1016/j.yexcr.2009.06.011. Epub 2009 Jun 18.

PMID:
19540229
32.

miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes.

Tan LP, Wang M, Robertus JL, Schakel RN, Gibcus JH, Diepstra A, Harms G, Peh SC, Reijmers RM, Pals ST, Kroesen BJ, Kluin PM, Poppema S, van den Berg A.

Lab Invest. 2009 Jun;89(6):708-16. doi: 10.1038/labinvest.2009.26. Epub 2009 Apr 6.

33.

Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile.

Gibcus JH, Tan LP, Harms G, Schakel RN, de Jong D, Blokzijl T, Möller P, Poppema S, Kroesen BJ, van den Berg A.

Neoplasia. 2009 Feb;11(2):167-76. Erratum in: Neoplasia. 2018 Jan 28;20(2):226.

34.

Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis.

Stel AJ, Ten Cate B, Jacobs S, Kok JW, Spierings DC, Dondorff M, Helfrich W, Kluin-Nelemans HC, de Leij LF, Withoff S, Kroesen BJ.

J Immunol. 2007 Feb 15;178(4):2287-95.

35.

Regulation of pri-microRNA BIC transcription and processing in Burkitt lymphoma.

Kluiver J, van den Berg A, de Jong D, Blokzijl T, Harms G, Bouwman E, Jacobs S, Poppema S, Kroesen BJ.

Oncogene. 2007 May 31;26(26):3769-76. Epub 2006 Dec 18.

PMID:
17173072
36.

The role of microRNAs in normal hematopoiesis and hematopoietic malignancies.

Kluiver J, Kroesen BJ, Poppema S, van den Berg A.

Leukemia. 2006 Nov;20(11):1931-6. Epub 2006 Sep 14. Review.

PMID:
16990772
37.

Functional inhibition of NF-kappaB signal transduction in alphavbeta3 integrin expressing endothelial cells by using RGD-PEG-modified adenovirus with a mutant IkappaB gene.

Ogawara K, Kułdo JM, Oosterhuis K, Kroesen BJ, Rots MG, Trautwein C, Kimura T, Haisma HJ, Molema G.

Arthritis Res Ther. 2006;8(1):R32. Epub 2006 Jan 13.

38.

Targeted induction of apoptosis for cancer therapy: current progress and prospects.

Bremer E, van Dam G, Kroesen BJ, de Leij L, Helfrich W.

Trends Mol Med. 2006 Aug;12(8):382-93. Epub 2006 Jun 23. Review.

PMID:
16798087
39.

PDMP sensitizes neuroblastoma to paclitaxel by inducing aberrant cell cycle progression leading to hyperploidy.

Dijkhuis AJ, Klappe K, Jacobs S, Kroesen BJ, Kamps W, Sietsma H, Kok JW.

Mol Cancer Ther. 2006 Mar;5(3):593-601.

40.

Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma.

Kluiver J, Haralambieva E, de Jong D, Blokzijl T, Jacobs S, Kroesen BJ, Poppema S, van den Berg A.

Genes Chromosomes Cancer. 2006 Feb;45(2):147-53.

PMID:
16235244
41.

BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas.

Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, Kroesen BJ, van den Berg A.

J Pathol. 2005 Oct;207(2):243-9.

PMID:
16041695
42.

Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.

Bremer E, Samplonius DF, Peipp M, van Genne L, Kroesen BJ, Fey GH, Gramatzki M, de Leij LF, Helfrich W.

Cancer Res. 2005 Apr 15;65(8):3380-8.

44.
45.

The role of B cell-mediated T cell costimulation in the efficacy of the T cell retargeting bispecific antibody BIS20x3.

Stel AJ, Kroesen BJ, Jacobs S, Groen H, de Leij LF, Kluin-Nelemans HC, Withoff S.

J Immunol. 2004 Nov 15;173(10):6009-16.

46.

Use of the EGP-2/Ep-CAM promoter for targeted expression of heterologous genes in carcinoma derived cell lines.

McLaughlin PM, Trzpis M, Kroesen BJ, Helfrich W, Terpstra P, Dokter WH, Ruiters MH, de Leij LF, Harmsen MC.

Cancer Gene Ther. 2004 Sep;11(9):603-12.

PMID:
15243630
47.
48.
49.

Observation of different ceramide species from crude cellular extracts by normal-phase high-performance liquid chromatography coupled to atmospheric pressure chemical ionization mass spectrometry.

Pettus BJ, Bielawska A, Kroesen BJ, Moeller PD, Szulc ZM, Hannun YA, Busman M.

Rapid Commun Mass Spectrom. 2003;17(11):1203-11.

PMID:
12772277
50.

High expression of B-cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma.

van den Berg A, Kroesen BJ, Kooistra K, de Jong D, Briggs J, Blokzijl T, Jacobs S, Kluiver J, Diepstra A, Maggio E, Poppema S.

Genes Chromosomes Cancer. 2003 May;37(1):20-8.

PMID:
12661002

Supplemental Content

Loading ...
Support Center